Insider Transactions in Q2 2021 at Acceleron Pharma Inc (XLRN)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2021
|
Adam M Veness SVP, General Counsel and Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.51%
|
$13,608
$126.69 P/Share
|
|
Apr 19
2021
|
Thomas A Mccourt Director |
SELL
Open market or private sale
|
Direct |
7,500
-17.42%
|
$892,500
$119.79 P/Share
|
|
Apr 19
2021
|
Thomas A Mccourt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+35.64%
|
$300,000
$40.61 P/Share
|
|
Apr 05
2021
|
Karen L. Smith Director |
SELL
Open market or private sale
|
Direct |
11,864
-55.77%
|
$1,660,960
$140.64 P/Share
|
|
Apr 05
2021
|
Karen L. Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,925
+20.54%
|
$383,775
$43.32 P/Share
|
|
Apr 05
2021
|
Joseph S Zakrzewski Director |
SELL
Open market or private sale
|
Direct |
10,000
-7.98%
|
$1,410,000
$141.29 P/Share
|
|
Apr 05
2021
|
Joseph S Zakrzewski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.35%
|
$240,000
$24.11 P/Share
|
|
Apr 01
2021
|
Karen L. Smith Director |
SELL
Open market or private sale
|
Direct |
8,925
-22.79%
|
$1,213,800
$136.4 P/Share
|
|
Apr 01
2021
|
Karen L. Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,925
+20.54%
|
$383,775
$43.32 P/Share
|
|
Apr 01
2021
|
Joseph S Zakrzewski Director |
SELL
Open market or private sale
|
Direct |
10,000
-6.01%
|
$1,340,000
$134.44 P/Share
|
|
Apr 01
2021
|
Joseph S Zakrzewski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.35%
|
$240,000
$24.11 P/Share
|